{"id":48357,"date":"2026-07-30T21:09:00","date_gmt":"2026-07-30T19:09:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5da6ecea4d3175e8c31be0b0e3e11044"},"modified":"2026-07-30T21:09:00","modified_gmt":"2026-07-30T19:09:00","slug":"capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=48357","title":{"rendered":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law"},"content":{"rendered":"<p>BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260730338978\/en\/2864420\/5\/BFA_Law_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260730338978\/en\/2864420\/22\/BFA_Law_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260730338978\/en\/2864420\/5\/BFA_Law_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260730338978\/en\/2864420\/21\/BFA_Law_Logo.jpg\" \/><\/a><p>NEW YORK--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/search?q=%24CAPR&src=ctag\" >$CAPR<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/BFA?src=hash\" >#BFA<\/a>--Leading securities law firm <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=Bleichmar+Fonti+%26+Auld+LLP&amp;index=1&amp;md5=22dc8a3c433fef78e8f11e50af4b8fa2\" rel=\"nofollow\" shape=\"rect\"><b>Bleichmar Fonti &amp; Auld LLP<\/b><\/a> announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop.<\/p><p>If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=2&amp;md5=454f36e07a9ff61581e37b265dbe7a02\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><b>.<\/b><\/p><p><b>Key Details of the Capricor Therapeutics ($CAPR) Class Action Investigation:<\/b><\/p><ul class=\"bwlistdisc\"><li><b>Investigation Overview: <\/b>Securities fraud relating to Capricor\u2019s statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.<\/li><li><b>Stock Decline: <\/b>July 27, 2026 \u2013 64.5% Stock Drop<\/li><li><b>Action: <\/b>Contact <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=BFA+Law&amp;index=3&amp;md5=f44d8dd46e59b57753d33a6bf2dd8d00\" rel=\"nofollow\" shape=\"rect\">BFA Law<\/a> to discuss your rights<\/li><\/ul><p><b>Why is Capricor Being Investigated for Securities Fraud?<\/b><\/p><p>Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy.<\/p><p>BFA is investigating whether Capricor misled investors about Deramiocel\u2019s clinical data, including the company\u2019s statements concerning positive topline results and its regulatory path with the FDA.<\/p><p><b>Why did Capricor\u2019s Stock Drop?<\/b><\/p><p>On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor\u2019s statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded.<\/p><p>This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day.<\/p><p><b>Click here for more information: <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=4&amp;md5=8d389b90e10e816115a715e62c651659\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><b>.<\/b><\/p><p><b>What Can You Do?<\/b><\/p><p>If you invested in Capricor Therapeutics securities, you may have legal options and are encouraged to submit your information to the firm.<\/p><p>All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p><p><b>Submit your information by visiting:<\/b><\/p><p class=\"bwalignc\"><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=5&amp;md5=cb7b86c71cb18ae5cae1576e5dd5be9b\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><\/p><p>Or contact:<\/p><p>Adam McCall<br\/><a  href=\"mailto:adam@bfalaw.com\" rel=\"nofollow\" shape=\"rect\">adam@bfalaw.com<\/a><br\/>212.789.3619<\/p><p><b>Why Bleichmar Fonti &amp; Auld LLP?<\/b><\/p><p>BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by <i>Chambers USA<\/i>, <i>The Legal 500<\/i>, and <i>ISS SCAS<\/i>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the <i>National Law Journal<\/i>, \u201cLitigation Stars\u201d by <i>Benchmark Litigation<\/i>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by <i>Lawdragon<\/i>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by <i>Law360<\/i> and \u201cSuperLawyers\u201d by Thomson Reuters.<\/p><p>Most recently, <i>The Legal 500 <\/i>awarded BFA the most client satisfaction accolades of any plaintiff\u2019s securities litigation law firm, with clients noting: \u201c[t]here is no better service provider in the practice area,\u201d \u201c[t]he interest of the client is always front and center,\u201d and \u201c[t]here isn\u2019t a better firm in this space.\u201d One testimonial described the firm as \u201cnimble and entrepreneurial,\u201d with a \u201crelentless focus on adding value for clients.\u201d<\/p><p>Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p><p>For more information about BFA and its attorneys, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com&amp;index=6&amp;md5=7dfb3c90cddb9bc0203c1372c35af8da\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.bfalaw.com<\/a>.<\/p><p class=\"bwalignc\"><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=7&amp;md5=317711224a43593fc2e0de2886990b94\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><\/p><p><i>Attorney advertising. Past results do not guarantee future outcomes.<\/i><\/p><br\/> <b>Contacts<\/b> <br\/><p class=\"bwalignl\">Adam McCall<br\/><a  href=\"mailto:adam@bfalaw.com\" rel=\"nofollow\" shape=\"rect\">adam@bfalaw.com<\/a><br\/>212.789.3619<\/p>","protected":false},"excerpt":{"rendered":"<p>BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.NEW YORK&#8211;(BUSINESS WIRE)&#8211;$CAPR #B&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-48357","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48357"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48357\/revisions"}],"predecessor-version":[{"id":48358,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/48357\/revisions\/48358"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}